Given the pivotal role of the CDK4/6-RB1 pathway in cell proliferation and cancer development, targeting CDK4/6 offers a valuable cancer treatment strategy, potentially arresting the cell cycle in the G1 phase and reducing cell survival. Here, CDK4 is linked to cancer.